Axsome Therapeutics (NASDAQ:AXSM) Director Sells $1,236,910.43 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman sold 5,537 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $223.39, for a total transaction of $1,236,910.43. Following the transaction, the director owned 29,603 shares of the company’s stock, valued at $6,613,014.17. This represents a 15.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Mark Coleman also recently made the following trade(s):

• On Monday, June 1st, Mark Coleman sold 6,000 shares of Axsome Therapeutics stock. The shares were sold at an average price of $230.30, for a total transaction of $1,381,800.00.
• On Friday, May 29th, Mark Coleman sold 6,000 shares of Axsome Therapeutics stock. The shares were sold at an average price of $233.46, for a total transaction of $1,400,760.00.

Axsome Therapeutics Stock Down 0.9%

AXSM opened at $231.48 on Friday. Axsome Therapeutics, Inc. has a fifty-two week low of $96.09 and a fifty-two week high of $238.56. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. The company has a fifty day moving average of $201.25 and a two-hundred day moving average of $178.04. The stock has a market capitalization of $11.91 billion, a price-to-earnings ratio of -62.06 and a beta of 0.61.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The firm had revenue of $191.20 million during the quarter, compared to analysts’ expectations of $191.10 million. The firm’s revenue for the quarter was up 57.4% compared to the same quarter last year. On average, research analysts expect that Axsome Therapeutics, Inc. will post -2.24 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on AXSM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Monday, April 20th. Oppenheimer set a $280.00 price objective on shares of Axsome Therapeutics in a report on Monday, May 4th. Royal Bank Of Canada lifted their price objective on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the company an “outperform” rating in a report on Tuesday, May 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $272.00 price objective on shares of Axsome Therapeutics in a report on Monday, May 4th. Finally, Truist Financial raised shares of Axsome Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.26.

Institutional Trading of Axsome Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Axsome Therapeutics by 6.0% during the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after purchasing an additional 235,626 shares in the last quarter. Franklin Street Advisors Inc. NC purchased a new stake in shares of Axsome Therapeutics during the fourth quarter worth about $1,826,000. Aberdeen Group plc increased its stake in shares of Axsome Therapeutics by 15.5% during the third quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock worth $11,495,000 after purchasing an additional 12,732 shares in the last quarter. TD Asset Management Inc increased its stake in shares of Axsome Therapeutics by 107.7% during the third quarter. TD Asset Management Inc now owns 44,192 shares of the company’s stock worth $5,367,000 after purchasing an additional 22,914 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its stake in shares of Axsome Therapeutics by 20.4% during the fourth quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company’s stock worth $79,643,000 after purchasing an additional 73,925 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.